With an aim to share expertise and diminish duplicative research and care efforts in amyotrophic lateral sclerosis (ALS), two nonprofits — EverythingALS and CureALS — are combining operations on the EverythingALS platform, with an emphasis on research. The new single nonprofit also will tackle efforts to find…

Spinogenix has launched a clinical trial in Australia to investigate its amyotrophic lateral sclerosis (ALS) treatment candidate SPG302 in patients and healthy volunteers. The first-in-human Phase 1 clinical trial (NCT05882695), which is recruiting up to 112 participants, is being conducted at the Nucleus Network Melbourne, Australia. Its…

Amylyx Pharmaceuticals Canada has entered into product listing agreements with Quebec and Ontario to publicly reimburse Albrioza (sodium phenylbutyrate and ursodoxicoltaurine), which was recently approved for amyotrophic lateral sclerosis (ALS). The oral therapy, which is marketed in the U.S. as Relyvrio, has been added to the…

NurOwn, an experimental treatment, significantly lowered neurofilament light chain (NfL) levels in the spinal fluid, a marker of nerve damage, and this seems to predict slower disease progression in amyotrophic lateral sclerosis (ALS) patients. That’s according to a new analysis of Phase 3 clinical trial (NCT03280056) data…

A grant given to a researcher at the University of Albany in New York will support further work into specific RNA molecules, called RNA aptamers, that have shown early promise in treating amyotrophic lateral sclerosis (ALS). The $768,825 U.S. Department of Defense award to Li Niu, PhD, a chemistry…

CNM-Au8 extended long-term survival and slowed disease progression in adults with early stage amyotrophic lateral sclerosis (ALS) compared with a placebo, according to final data from the RESCUE-ALS clinical trial and one-year findings in its open-label extension (OLE). Patients treated initially with CNM-Au8 in the main trial experienced…

The technology company Unlearn has joined with QurAlis to use artificial intelligence (AI) to speed up clinincal trials for amyotrophic lateral sclerosis (ALS). The aim of the collaboration is to minimize variability and increase the statistical strength of QurAlis’ clinical trials that are evaluating their primary ALS…

Arrowhead Pharmaceuticals has filed an application in Australia seeking the green light to launch the first clinical trial of ARO-SOD1, its RNA-based therapy for amyotrophic lateral sclerosis (ALS). The therapy is designed to reduce SOD1 protein levels in ALS patients carrying SOD1 mutations, which are estimated to account…

High blood levels of an omega-3 fatty acid is associated with a significantly slower disease progression and longer life among people with amyotrophic lateral sclerosis (ALS), a study reported. The link specifically was seen in people with elevated blood levels of an omega-3 fatty acid called alpha-linolenic acid…

A new genetic risk score that takes hundreds of different genetic variations into account may help predict who’s most likely to develop amyotrophic lateral sclerosis (ALS). The score needs to be validated in future studies before being used in the clinic, but could be important to stratify people according…